Status:
TERMINATED
Zinc Sulfate for Human Papillomavirus (HPV)
Lead Sponsor:
Corewell Health West
Conditions:
Human Papilloma Virus
Eligibility:
FEMALE
21-65 years
Phase:
NA
Brief Summary
The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous ...
Detailed Description
Upon enrollment eligible participants will be randomized and given a three-month supply of zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at enrollment and upon...
Eligibility Criteria
Inclusion
- Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on Pap smear OR
- Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR
- Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)
Exclusion
- Patients who proceed to excisional procedures (loop electrosurgical excision procedure or cold knife conization)
- Pregnant patients
- Breastfeeding patients
- Immunocompromised patients
Key Trial Info
Start Date :
October 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2019
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03404310
Start Date
October 24 2017
End Date
June 28 2019
Last Update
September 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spectrum Health
Grand Rapids, Michigan, United States, 49503